{{Drugbox | Verifiedfields = verified | Watchedfields = verified | verifiedrevid = 445399889 | image = Bremelanotide structure.svg | image_class = skin-invert-image | width = 250 | alt = | pronounce = | tradename = Vyleesi | Drugs.com = | MedlinePlus = a619054 | licence_CA = | licence_EU = | DailyMedID = Bremelanotide | licence_US = | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = Subcutaneous | class = Melanocortin receptor agonist | ATCvet = | ATC_prefix = G02 | ATC_suffix = CX05 | ATC_supplemental = | legal_AU = | legal_AU_comment = | legal_BR = | legal_BR_comment = | legal_CA = | legal_CA_comment = | legal_DE = | legal_DE_comment = | legal_NZ = | legal_NZ_comment = | legal_UK = | legal_UK_comment = | legal_US = Rx-only | legal_US_comment = | legal_UN = | legal_UN_comment = | legal_status =
| bioavailability = : ~100% | protein_bound = 21% | metabolism = Hydrolysis of peptide bonds | metabolites = | onset = | elimination_half-life = 2.7 hours | duration_of_action = | excretion = Urine: 64.8%Feces: 22.8%
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).